Lynch & Associates Agenus Inc Transaction History

Lynch & Associates

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 09, 2024	BUY	$0.53 - $0.93 $8,480 - $14,880	16,000 Added 37.56%	58,600 $33,000
Q3 2023 Oct 24, 2023	SELL	$1.12 - $1.88 $4,681 - $7,858	-4,180 Reduced 8.94%	42,600 $48,000
Q1 2023 Apr 04, 2023	BUY	$1.45 - $2.95 $1,740 - $3,540	1,200 Added 2.63%	46,780 $71,000
Q4 2022 Oct 24, 2023	BUY	$2.02 - $3.25 $6,019 - $9,685	2,980 Added 7.0%	45,580 $109,000
Q4 2022 Jan 05, 2023	BUY	$2.02 - $3.25 $35,350 - $56,875	17,500 Added 62.32%	45,580 $109,000
Q1 2022 Apr 08, 2022	BUY	$2.35 - $3.47 $705 - $1,041	300 Added 1.08%	28,080 $69,000
Q4 2021 Jan 11, 2022	BUY	$2.92 - $5.74 $3,758 - $7,387	1,287 Added 4.86%	27,780 $89,000
Q3 2021 Oct 12, 2021	BUY	$4.98 - $6.63 $26,857 - $35,755	5,393 Added 25.56%	26,493 $139,000
Q2 2021 Jul 21, 2021	BUY	$2.56 - $5.49 $6,400 - $13,725	2,500 Added 13.44%	21,100 $116,000
Q1 2021 Apr 09, 2021	BUY	$2.69 - $5.25 $6,725 - $13,125	2,500 Added 15.53%	18,600 $51,000
Q3 2020 Oct 21, 2020	BUY	$2.98 - $5.2 $7,450 - $13,000	2,500 Added 18.38%	16,100 $64,000
Q1 2020 Apr 28, 2020	BUY	$1.92 - $4.39 $26,112 - $59,703	13,600 New	13,600 $33,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

Stay updated on Lynch & Associates with notifications on news.